NRD
ZNTL icon

Nebula Research & Development’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Nebula Research & Development’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-14,167
Closed -$42.9K – 1174
2024
Q4 		$42.9K Sell
14,167
-15,024
-51% -$49.2K 0.01% 870
2024
Q3 		$107K Buy
+29,191
New +$106K 0.01% 873

Other funds holding ZNTL

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Nebula Research & Development's ZNTL Position: Q1 2025 in Review

Nebula Research & Development sold out of Zentalis Pharmaceuticals (ZNTL) in Q1 2025, closing a stake of 14,167 shares — an estimated $42.9K sold.

Nebula Research & Development first reported a position in ZNTL in Q3 2024 and held it in 2 quarters. The position peaked at $107K in Q3 2024. 132 funds tracked by Wall St. Rank hold ZNTL as of Q1 2025.

  • Nebula Research & Development reported no remaining Zentalis Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Nebula Research & Development sold 14,167 Zentalis Pharmaceuticals shares in Q1 2025, an estimated $42.9K.
  • Nebula Research & Development first reported a position in Zentalis Pharmaceuticals in Q3 2024 and held it in 2 quarters.
  • Nebula Research & Development's Zentalis Pharmaceuticals position peaked at $107K in Q3 2024.
  • 132 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q1 2025.

Based on Nebula Research & Development's 13F filing for Q1 2025, filed 15 May 2025.